LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 386

Search options

  1. Book: Hematopoietic cell transplantation for malignant conditions

    Bashir, Qaiser / Hamadani, Mehdi

    2019  

    Author's details edited by Qaiser Bashir, Mehdi Hamadani
    Keywords Cancer/Chemotherapy ; Hematopoietic stem cells/Transplantation
    Subject code 616.994061
    Language English
    Size x, 428 Seiten, Illustrationen, Diagramme, 25 cm
    Publisher St. Louis, Missouri
    Publishing place Amsterdam
    Publishing country United States
    Document type Book
    HBZ-ID HT020027383
    ISBN 978-0-323-56802-9 ; 9780323568036 ; 0-323-56802-5 ; 0323568033
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    2019 A 527 available for loan (reading room) Lesesaal EG

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Did brentuximab vedotin's rise to the top ECHELON of Hodgkin therapeutics invalidate AETHERA results?

    Hamadani, Mehdi

    Haematologica

    2022  Volume 107, Issue 7, Page(s) 1500–1502

    MeSH term(s) Antibodies, Monoclonal/therapeutic use ; Antineoplastic Agents/therapeutic use ; Brentuximab Vedotin ; Hodgkin Disease/drug therapy ; Humans ; Immunoconjugates/therapeutic use
    Chemical Substances Antibodies, Monoclonal ; Antineoplastic Agents ; Immunoconjugates ; Brentuximab Vedotin (7XL5ISS668)
    Language English
    Publishing date 2022-07-01
    Publishing country Italy
    Document type Journal Article ; Comment
    ZDB-ID 2333-4
    ISSN 1592-8721 ; 0017-6567 ; 0390-6078
    ISSN (online) 1592-8721
    ISSN 0017-6567 ; 0390-6078
    DOI 10.3324/haematol.2021.280284
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.76: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data.

    Furqan, Fateeha / Hamadani, Mehdi

    Therapeutic advances in hematology

    2022  Volume 13, Page(s) 20406207221087511

    Abstract: Loncastuximab tesirine-lpyl (ADC Therapeutics) is an anti-CD19 antibody-drug conjugate which consists of anti-CD19 antibody and cytotoxic alkylating agent, SG3199. Data from ... ...

    Abstract Loncastuximab tesirine-lpyl (ADC Therapeutics) is an anti-CD19 antibody-drug conjugate which consists of anti-CD19 antibody and cytotoxic alkylating agent, SG3199. Data from preclinical
    Language English
    Publishing date 2022-03-22
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2585183-4
    ISSN 2040-6215 ; 2040-6207
    ISSN (online) 2040-6215
    ISSN 2040-6207
    DOI 10.1177/20406207221087511
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Bridging the Gap: Early Transition and Hybrid Models of Care to Improve Access to Chimeric Antigen Receptor T Cell Therapy.

    Ahmed, Nausheen / Mahmoudjafari, Zahra / Hamadani, Mehdi / Hashmi, Hamza

    Transplantation and cellular therapy

    2023  Volume 29, Issue 6, Page(s) 399–402

    MeSH term(s) Receptors, Chimeric Antigen/genetics ; Receptors, Chimeric Antigen/therapeutic use ; Immunotherapy, Adoptive ; Receptors, Antigen, T-Cell/genetics ; Receptors, Antigen, T-Cell/therapeutic use ; Cell- and Tissue-Based Therapy
    Chemical Substances Receptors, Chimeric Antigen ; Receptors, Antigen, T-Cell
    Language English
    Publishing date 2023-03-27
    Publishing country United States
    Document type Letter
    ZDB-ID 3062231-1
    ISSN 2666-6367
    ISSN (online) 2666-6367
    DOI 10.1016/j.jtct.2023.03.021
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5082: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Advances in Transplantation for Lymphomas Resulting from CIBMTR Lymphoma Working Committee's Research Portfolio: A Five-Year Report (2013-2018).

    Hamadani, Mehdi

    Advances in cell and gene therapy

    2018  Volume 1, Issue 3

    Abstract: The Center for International Blood and Marrow Transplant Research (CIBMTR) is a research collaboration between the National Marrow Donor Program (NMDP)/Be The Match and the Medical College of Wisconsin (MCW). The CIBMTR collaborates with the global ... ...

    Abstract The Center for International Blood and Marrow Transplant Research (CIBMTR) is a research collaboration between the National Marrow Donor Program (NMDP)/Be The Match and the Medical College of Wisconsin (MCW). The CIBMTR collaborates with the global scientific community to advance hematopoietic cell transplantation (HCT) and cellular therapy worldwide to increase survival and enrich quality of life for patients. The observation research program within CIBMTR is organized into 15 working committees. This review is aiming to highlight the observational research studies published by the CIBMTR Lymphoma Working committee over the last five years (2013-18) and to summarize how these studies have impacted the field by helping inform clinical practice in scenarios where prospective data from high quality randomized trials were not available or where owing to the rarity of a particular transplant indication such data were unlikely to be generated, outside the setting of a large observational research database. The salient findings reviewed include; (a) studies supporting role of autologous HCT in diffuse large B-cell lymphoma (DLBCL) patients with sensitive relapse of disease within one year of diagnosis, (b) role of autologous HCT vs allogeneic HCT in follicular lymphoma patients with early therapy failure, (c) prognostic scoring system development for classical Hodgkin lymphoma and DLBCL patients with prior autograft failure, (d) defining the role of alternative donor transplantation in lymphomas, (e) evaluating appropriate conditioning regimens for HCT in lymphoma, and (f) outcomes of HCT in rare lymphoid malignancies.
    Language English
    Publishing date 2018-08-30
    Publishing country United States
    Document type Journal Article
    ISSN 2573-8461
    ISSN (online) 2573-8461
    DOI 10.1002/acg2.17
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article ; Online: Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma?

    Shah, Nirav N / Hamadani, Mehdi

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2021  Volume 39, Issue 5, Page(s) 487–498

    MeSH term(s) Hematopoietic Stem Cell Transplantation/methods ; Humans ; Immunotherapy, Adoptive/methods ; Lymphoma/therapy ; Lymphoma, Large B-Cell, Diffuse/therapy ; Lymphoma, Mantle-Cell/therapy ; Randomized Controlled Trials as Topic ; Transplantation, Homologous
    Language English
    Publishing date 2021-01-12
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.20.01447
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1847: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 650: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors.

    Epperla, Narendranath / Hamadani, Mehdi

    Hematology. American Society of Hematology. Education Program

    2021  Volume 2021, Issue 1, Page(s) 247–253

    Abstract: The approval of brentuximab vedotin (BV) and checkpoint inhibitors (CPI) has revolutionized the management of relapsed/refractory classical Hodgkin lymphoma (cHL) patients. In recent years these agents have rapidly moved to earlier lines of therapy, ... ...

    Abstract The approval of brentuximab vedotin (BV) and checkpoint inhibitors (CPI) has revolutionized the management of relapsed/refractory classical Hodgkin lymphoma (cHL) patients. In recent years these agents have rapidly moved to earlier lines of therapy, including post-autologous hematopoietic cell transplant (auto-HCT) consolidation, pre-HCT salvage, and the frontline treatment setting. This shift in practice means that double-refractory (refractory to both BV and CPI) cHL is becoming an increasingly common clinical problem. In patients who are not eligible for clinical trials, conventional cytotoxic and targeted therapies (off label) may be a potential option. In patients who are transplant eligible, early referral to allogeneic HCT should be considered given the significant improvement in transplant outcomes in the contemporary era. Cellular therapy options including CD30.chimeric antigen receptor T cells, Epstein-Barr virus-directed cytotoxic T cells, and CD16A/30 bispecific natural killer cell engagers appear promising and are currently in clinical trials.
    MeSH term(s) Adult ; Antineoplastic Agents, Immunological/therapeutic use ; Brentuximab Vedotin/therapeutic use ; Hematopoietic Stem Cell Transplantation ; Hodgkin Disease/radiotherapy ; Hodgkin Disease/therapy ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Male ; Neoplasm Recurrence, Local/therapy ; Transplantation, Autologous
    Chemical Substances Antineoplastic Agents, Immunological ; Immune Checkpoint Inhibitors ; Brentuximab Vedotin (7XL5ISS668)
    Language English
    Publishing date 2021-12-24
    Publishing country United States
    Document type Case Reports ; Journal Article ; Review
    ZDB-ID 2084287-9
    ISSN 1520-4383 ; 1520-4391
    ISSN (online) 1520-4383
    ISSN 1520-4391
    DOI 10.1182/hematology.2021000256
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.

    Ahmed, Nausheen / Hamadani, Mehdi

    Expert review of anticancer therapy

    2021  Volume 21, Issue 12, Page(s) 1313–1320

    Abstract: Introduction: Relapsed or refractory diffuse large B cell lymphoma (DLBCL) has a poor prognosis. Several novel therapies have gained regulatory approval for treatment of DLBCL, however there is still a need for additional therapies to be added to the ... ...

    Abstract Introduction: Relapsed or refractory diffuse large B cell lymphoma (DLBCL) has a poor prognosis. Several novel therapies have gained regulatory approval for treatment of DLBCL, however there is still a need for additional therapies to be added to the armamentarium. Loncastuximab tesirine-lpyl (ADC Therapeutics), an anti-CD19 antibody-drug conjugate (ADC), was recently approved for the treatment of relapsed, refractory diffuse large B-cell lymphoma (DLBCL).
    Areas covered: We review the design and pharmacologic characteristics of loncastuximab tesirine-lpyl, emphasizing on the significance of CD19 as an effective target as well as pyrrolobenzodiazepine (PBD) as an effective payload. We review the key findings of the phase 1 LOTIS-1 and Phase 2 LOTIS-2 trials of loncastuximab in DLBCL, including efficacy and toxicity profile.
    Expert opinion: Key findings in the early-phase trial support the efficacy of Loncastuximab in DLBCL, including in high-risk subgroups. The side effects have been tolerable even in elderly patients (≥75 years). Several ongoing clinical trials are currently evaluating the safety and efficacy of loncastuximab tesirine in a variety of NHL subtypes, as well as the study of combination strategies.
    MeSH term(s) Aged ; Antibodies, Monoclonal, Humanized/adverse effects ; Antigens, CD19/therapeutic use ; Benzodiazepines ; Humans ; Immunoconjugates/adverse effects ; Lymphoma, Large B-Cell, Diffuse/chemically induced ; Lymphoma, Large B-Cell, Diffuse/drug therapy
    Chemical Substances Antibodies, Monoclonal, Humanized ; Antigens, CD19 ; Immunoconjugates ; Benzodiazepines (12794-10-4) ; loncastuximab tesirine (7K5O7P6QIU)
    Language English
    Publishing date 2021-10-17
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2112544-2
    ISSN 1744-8328 ; 1473-7140
    ISSN (online) 1744-8328
    ISSN 1473-7140
    DOI 10.1080/14737140.2021.1988853
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5907: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine.

    Epperla, Narendranath / Hamadani, Mehdi

    Current hematologic malignancy reports

    2021  Volume 16, Issue 1, Page(s) 19–24

    Abstract: Purpose of review: There are limited treatment options for relapsed/refractory classical Hodgkin lymphoma (cHL) patients who progress on brentuximab vedotin and programmed death-1 inhibitors. Camidanlumab Tesirine (Cami) is a new agent that has shown ... ...

    Abstract Purpose of review: There are limited treatment options for relapsed/refractory classical Hodgkin lymphoma (cHL) patients who progress on brentuximab vedotin and programmed death-1 inhibitors. Camidanlumab Tesirine (Cami) is a new agent that has shown activity in multiply relapsed/refractory cHL patients. In this review, we provide a comprehensive overview of Cami.
    Recent findings: In phase 1 study of Cami in relapsed/refractory cHL and non-Hodgkin lymphomas (NHL), Cami was noted to be safe with encouraging clinic activity in multiply relapsed/refractory cHL. Treatment-emergent adverse events (TEAEs) were reported in 95% (n = 73 of 77) of patients, while grade 3 TEAEs were reported in 66% (n = 51) of cHL patients. Cami was associated with immune-related adverse events (irAEs) including peripheral sensory neuropathy, Guillain-Barré syndrome (GBS)/radiculopathy, colitis, hypothyroidism, hyperthyroidism, thyroiditis, and pneumonitis. The overall response rate (ORR) and complete (CR) rate were 71%/40% in the cHL cohort (n = 75). In the interim analysis of an ongoing phase 2 study in 2020, Cami demonstrated good clinical efficacy with an ORR/CR rate of 83%/38% among the 47 evaluable cHL patients. The toxicity profile was similar to that seen in the phase 1 study, with no new safety signals.. As the phase 2 study with Cami is continuing to accrue patients and we await the final results, the preliminary results with Cami are encouraging and provide an additional therapeutic option especially for patients with multiply relapsed/refractory cHL and perhaps other hematological malignancies expression CD25.
    MeSH term(s) Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Agents, Immunological/therapeutic use ; Clinical Trials as Topic ; Hodgkin Disease/drug therapy ; Hodgkin Disease/immunology ; Humans ; Immunoconjugates/adverse effects ; Immunoconjugates/therapeutic use ; Interleukin-2 Receptor alpha Subunit/antagonists & inhibitors ; Interleukin-2 Receptor alpha Subunit/immunology ; Molecular Targeted Therapy ; Treatment Outcome
    Chemical Substances Antineoplastic Agents, Immunological ; Immunoconjugates ; Interleukin-2 Receptor alpha Subunit
    Language English
    Publishing date 2021-01-25
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2229765-0
    ISSN 1558-822X ; 1558-8211
    ISSN (online) 1558-822X
    ISSN 1558-8211
    DOI 10.1007/s11899-021-00604-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6332: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article: Experimental Pharmaceuticals for Steroid-Refractory Acute Graft-versus-Host Disease.

    Abedin, Sameem / Hamadani, Mehdi

    Journal of experimental pharmacology

    2020  Volume 12, Page(s) 549–557

    Abstract: Acute GVHD (aGVHD) is a significant complication after allogeneic hematopoietic cell transplantation (HCT), occurring in up to 70% of HCT recipients. Steroid-refractory aGVHD represents a subset of patients failing initial therapy and is particularly ... ...

    Abstract Acute GVHD (aGVHD) is a significant complication after allogeneic hematopoietic cell transplantation (HCT), occurring in up to 70% of HCT recipients. Steroid-refractory aGVHD represents a subset of patients failing initial therapy and is particularly morbid, with only 30% of patients surviving long term. Better therapies are urgently required for these patients. Here, we discuss recent advancements in the management of SR-aGVHD. We review the currently available therapies for SR-aGVHD including the results of the REACH1 and REACH2 trials, which provide the basis for the use of ruxolitinib for the treatment of SR-aGVHD. We additionally discuss newer agents under clinical investigation and will highlight the niche these agents may fill to further improve outcomes in aGVHD patient care.
    Language English
    Publishing date 2020-11-26
    Publishing country New Zealand
    Document type Journal Article ; Review
    ZDB-ID 2587465-2
    ISSN 1179-1454
    ISSN 1179-1454
    DOI 10.2147/JEP.S259290
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top